Frank Vinluan is a senior biopharma reporter at MedCity News. He covers a range of topics within medicine and healthcare, with a focus on pharmaceuticals, medical technology, and financial services, particularly in areas such as immunology, oncology, and gene therapy. Frank's work has been featured in NewsBreak, MedCity News, RamaOnHealthcare, and Breaking Media, Inc.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Frank Vinluan's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions, drug development, FDA approvals, and biotech. He frequently cites data in his articles, indicating a reliance on factual evidence.
Given his focus on M&A deals and drug developments within the healthcare sector, Frank may be interested in receiving pitches related to exclusive insights from industry experts or company executives involved in these transactions or new developments. Pitches emphasizing unique data-driven analyses or perspectives from key opinion leaders could also resonate well with him.
As there is no specific geographic focus mentioned for Frank's reporting, relevant news or expert analysis from any location within the global pharmaceutical and biotech industries would likely be of interest to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Frank Vinluan
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.
By: Frank Vinluan
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology.
By: Frank Vinluan
Fulcrum Therapeutics drug pociredir posted early clinical trial results showing signs of treating sickle cell disease with no reports of serious complications. But the biotech is discontinuing this program due to FDA concerns that drugs in this class of medicines raise the risk of cancer.
By: Frank Vinluan
Rick Pazdur, formerly the FDA’s top oncology official, said the FDA is at a critical juncture that could determine the direction of the world’s top regulator of medicines. Pazdur spoke during a STAT panel discussion during the annual meeting of the American Society of Clinical Oncology.
By: Frank Vinluan
Ona Therapeutics’ antibody drug conjugates come from a platform technology that discovers novel antigens intended to enable the therapies to overcome drug resistance. The Spain-based startup’s lead ADC is on track to begin clinical testing in breast cancer.
By: Frank Vinluan
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product.
By: Frank Vinluan
GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year.
By: Frank Vinluan
Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will support a lead program zolucatetide, which is in development for a rare type of tumor with limited treatment options.
By: Frank Vinluan
Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-approved medicines. Del-brax is one of three RNA therapies from Novartis’s $12 billion acquisition of Avidity Biosciences.
By: Frank Vinluan
FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data.
